Physician profile
Jared D Bunevich
NPI 1144489386
$6,370.40
in general payments reported to CMS, 2019-2025
27 companies · $998 in 2025
The $998 reported for 2025 was more than what 86% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $567 · 2021: $856 · 2022: $1,185 · 2023: $1,009 · 2024: $717 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $1,103.99 | 2019-2023 | Acclarent Aera, Relieva Tract |
| Davol INC. | $852.25 | 2019-2025 | Arista Ah Flexitip, Arista |
| Integra Lifesciences Corporation | $614.32 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Inspire Medical Systems, INC. | $519.22 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $357.58 | 2022-2025 | Nucala |
| Stryker Corporation | $344.69 | 2019-2025 | Scopis Ent, Na |
| Intersect Ent, INC. | $285.49 | 2019-2021 | |
| Advanced Bionics, LLC | $269.08 | 2022 | |
| Checkpoint Surgical, INC | $223.93 | 2021-2022 | |
| Becton, Dickinson and Company | $208.23 | 2022-2023 | Arista Ah Flexitip |
| Genzyme Corporation | $184.12 | 2024 | |
| Smith+Nephew, INC. | $172.09 | 2019-2024 | Coblation |
| Kerecis Limited | $157.33 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Cochlear Americas | $146.32 | 2019-2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Musculoskeletal Transplant Foundation INC. | $132.85 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atos Medical INC | $130.17 | 2021-2022 | |
| Optinose US, INC. | $127.23 | 2019-2024 | |
| Kls-Martin L.P. | $98.08 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $95.49 | 2025 | Dupixent |
| Axogen | $82.92 | 2021 | |
| Medtronic, INC. | $78.79 | 2025 | Propel |
| Medtronic USA, INC. | $69.74 | 2019 | |
| Ethicon US, LLC | $46.62 | 2019 | |
| Alk-Abello, INC | $19.07 | 2019 | |
| Acera Surgical, INC. | $18.98 | 2025 | Restrata Wound Matrix |
| Tactile Systems Technology INC | $16.28 | 2023 | Entre Plus, Flexitouch Plus |
| Astrazeneca Pharmaceuticals LP | $15.54 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Bunevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.